Metropolitan Life Insurance CO Xeris Biopharma Holdings, Inc. Transaction History

Metropolitan Life Insurance CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$2.04 - $3.22 $12 - $19	-6 Reduced 0.15%	4,068 $8,000
Q4 2023 Feb 14, 2024	BUY	$1.47 - $2.36 $5,988 - $9,614	4,074 New	4,074 $9,000
Q1 2023 May 15, 2023	SELL	$1.03 - $1.63 $1,247 - $1,973	-1,211 Reduced 14.18%	7,329 $11,000
Q4 2022 Jun 14, 2023	BUY	$1.14 - $1.65 $1,380 - $1,998	1,211 Added 16.52%	8,540 $11.4 Million
Q4 2022 Mar 30, 2023	BUY	$1.14 - $1.65 $7,683 - $11,121	6,740 Added 374.44%	8,540 $11,000
Q4 2022 Feb 15, 2023	BUY	$1.14 - $1.65 $7,683 - $11,121	6,740 Added 374.44%	8,540 $11,000
Q3 2022 Jun 14, 2023	SELL	$1.37 - $1.93 $7,574 - $10,670	-5,529 Reduced 75.44%	1,800 $2.81 Million
Q3 2022 Mar 30, 2023	SELL	$1.37 - $1.93 $8,799 - $12,396	-6,423 Reduced 78.11%	1,800 $2,000
Q3 2022 Nov 14, 2022	SELL	$1.37 - $1.93 $8,799 - $12,396	-6,423 Reduced 78.11%	1,800 $3,000
Q2 2022 Jun 20, 2023	BUY	$1.48 - $2.64 $1,323 - $2,360	894 Added 12.2%	8,223 $12,000
Q2 2022 Mar 30, 2023	SELL	$1.48 - $2.64 $469 - $836	-317 Reduced 3.71%	8,223 $12,000
Q2 2022 Aug 11, 2022	BUY	$1.48 - $2.64 $12,170 - $21,708	8,223 New	8,223 $13,000

143

60M

148K

45.7K

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $462M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.